Comments
Roche banks on new drugs as Herceptin faces hurdle
06.09.2012. | LONDON (Reuters) - Swiss drugmaker Roche Holding AG expects results from 19 late-stage clinical trials over the next 18 months, providing a stream of products to offset a potential near-term threat to breast cancer drug Herceptin, its third biggest seller....
